These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
783 related items for PubMed ID: 16707599
1. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599 [Abstract] [Full Text] [Related]
5. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335 [Abstract] [Full Text] [Related]
12. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP. Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):1-5. PubMed ID: 15946498 [Abstract] [Full Text] [Related]
13. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422 [Abstract] [Full Text] [Related]
15. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A, Prasad K. J Assoc Physicians India; 2007 Feb 20; 55():109-13. PubMed ID: 17571739 [Abstract] [Full Text] [Related]
16. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Clin Cancer Res; 2009 Feb 01; 15(3):1059-63. PubMed ID: 19188180 [Abstract] [Full Text] [Related]
18. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. Clin Cancer Res; 2007 Dec 01; 13(23):7080-5. PubMed ID: 18056186 [Abstract] [Full Text] [Related]
19. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376 [Abstract] [Full Text] [Related]
20. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA. Am J Hematol; 2003 Aug 15; 73(4):249-55. PubMed ID: 12879428 [Abstract] [Full Text] [Related] Page: [Next] [New Search]